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Abstract
Background: Young men with mutations in the gene for the INSL3 receptor (Relaxin family peptide 2, RXFP2) are at risk of
reduced bone mass and osteoporosis. Consistent with the human phenotype, bone analyses of Rxfp2
2/2 mice showed
decreased bone volume, alterations of the trabecular bone, reduced mineralizing surface, bone formation, and osteoclast
surface. The aim of this study was to elucidate the INSL3/RXFP2 signaling pathways and targets in human osteoblasts.
Methodology/Principal Findings: Alkaline phosphatase (ALP) production, protein phosphorylation, intracellular calcium,
gene expression, and mineralization studies have been performed. INSL3 induced a significant increase in ALP production,
and Western blot and ELISA analyses of multiple intracellular signaling pathway molecules and their phosphorylation status
revealed that the MAPK was the major pathway influenced by INSL3, whereas it does not modify intracellular calcium
concentration. Quantitative Real Time PCR and Western blotting showed that INSL3 regulates the expression of different
osteoblast markers. Alizarin red-S staining confirmed that INSL3-stimulated osteoblasts are fully differentiated and able to
mineralize the extracellular matrix.
Conclusions/Significance: Together with previous findings, this study demonstrates that the INSL3/RXFP2 system is
involved in bone metabolism by acting on the MAPK cascade and stimulating transcription of important genes of osteoblast
maturation/differentiation and osteoclastogenesis.
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Introduction
Sex hormones have a critical role in bone metabolism [1,2]. In
particular, in the male, androgens are necessary for the gain of
bone mass during puberty and its maintenance during adulthood
[1,2]. Another testis-specific, Leydig cell derived hormone with a
recently identified role in bone metabolism is Insulin-like factor 3
(INSL3) [3–5]. INSL3 is a member of the relaxin-insulin family
peptide and it was initially characterized as an essential hormone
for the correct descent of the testes into the scrotum during fetal
life [3]. Apart from this role in physiological and pathological
testicular descent [6], INSL3 has recently gained further attention
for its possible roles in adulthood [7,8]. In fact, INSL3 is
produced constitutively but in a differentiation-dependent
manner by the Leydig cells under the long-term Leydig cell
differentiation effect of LH, and substantial circulating INSL3
levels are present in adult men (500–1000 pg/mL) [3,9,10].
Reduced plasma concentrations of INSL3 are seen in situations
of undifferentiated or altered Leydig cell status (such as
hypogonadism and ageing), and INSL3 has been suggested to
be even more sensitive than testosterone to impaired Leydig cell
function [3,8,9]. INSL3 could be therefore responsible for, or
contribute to, some clinical signs of hypogonadism currently
attributed to testosterone deficiency.
Following this hypothesis, we recently showed that young men
with mutations in the gene for the INSL3 receptor (Relaxin family
peptide 2, RXFP2) are at risk of reduced bone mass and
osteoporosis, despite their testosterone plasma levels are within
the normal range [4]. INSL3 induced a significant and dose-
dependent increase in cAMP and proliferation of human primary
osteoblasts, supporting a RXFP2-mediated role of INSL3 in
osteoblasts function [4,11].
Consistent with the human phenotype, bone histomorphometric
and mCT analyses at the lumbar and femoral sites of Rxfp2
2/2
mice showed decreased bone volume, alterations of the trabecular
bone, reduced mineralizing surface, bone formation, and osteo-
clast surface [4]. These data suggested that the low bone mass
phenotype in the Rxfp2
2/2 mice is linked to functional osteoblast
impairment causing little bone formation, little mineralizing
surface, and ultimately, a negative balance between bone
formation and bone resorption [4].
To better understand the molecular mechanisms by which
INSL3 acts on human osteoblasts, in this study we analyzed the
effects of this hormone on human osteoblasts on different signaling
pathways (intracellular calcium mobilization, protein phosphory-
lation and gene expression) that could be influenced by a G-
protein coupled receptor (GPCR) as RXFP2. This is particularly
intriguing in the light of a recent study by Kaftanovskaya et al. [12]
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29733that demonstrated that b-catenin, a critical protein for normal
bone development [13], could be a potential INSL3 target during
gubernaculum development, suggesting that INSL3 could exert its
action on osteoblasts not only via intracellular cAMP regulation.
Results
INSL3 stimulates alkaline phosphatase (ALP) production
by human osteoblasts
To test the viability of human osteoblasts stimulated with INSL3
and its possible toxicity we performed a TUNEL test that showed
the DNA integrity of osteoblasts and the absence of apoptosis at
any INSL3 concentration (1 nM, 10 nM and 100 nM) (Figure 1A).
INSL3 stimulation (at 1 nM, 10 nM and 100 nM) induced a
significant increase in the production of ALP, the most important
osteoblast marker, as evidenced by quantitative RT-PCR
(Figure 1B) and immunoenzymatic assay (Figure 1C).
INSL3 influences protein phosphorylation but not
intracellular calcium concentration
To investigate whether the INSL3/RXFP2 system influences the
phosphorylation of several key proteins, we stimulated human
osteoblasts with different INSL3 concentrations (1 nM, 10 nM, 100
nM) for short time periods (5, 10, 15, 30, 45 minutes) and then we
performed Western blot analysis. MEK and ERK showed a similar
trend, with and increase in phosphorylation at 5–15 minutes and
then a decrease at 30–45 min in a dose dependent manner
(Figure 2). This observation was further supported by ELISA
(Figure 3D and F) and densitometric analysis (Figure 3E and G).
Integrin key proteins (Src and PYK2), PLCb3 and b-catenin were
Figure 1. Evaluation of INSL3 toxicity and its effects on ALP production in human osteoblasts. A. TUNEL analysis on human osteoblasts
stimulated overnight with INSL3 at 1 nM, 10 nM and 100 nM. Positive control is obtained treating cells with DNase. Green fluorescence indicates DNA
fragmentation. Nuclei were counterstained with DAPI (Blue). B. Quantitative RT-PCR for ALP in human osteoblasts stimulated with INSL3 at different
concentrations. Quantification was normalized to the expression of the housekeeping gene b2-microglobulin on control (no stimulation). Data are
shown as the mean 6 standard deviation (SD) of the mean of three different experiments performed in triplicate. C. Immunoenzymatic assay of ALP
production in human osteoblasts after a 24 hour stimulation with INSL3 at different concentration. Control is obtained without stimulation. Data are
shown as the mean 6 standard deviation (SD) of the mean of three different experiments performed in triplicate. * P,0.05 vs control.
doi:10.1371/journal.pone.0029733.g001
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change in cRaf inhibitory phosphorylation at S259 [14].
In the same way no variation in phosphorylations were observed
for the Akt pathway (Akt and GSK3b) (Figure 2). These data were
further supported by ELISA (Figure 3A) and densitometric
analysis of Western blotting (Figure 3B and C). Finally, NF-kB
signaling (NF-kB, IKKa, IKKb,I kBa) was not affected by INSL3
(Figure 2). All these results were also confirmed by densitometric
analysis (data not shown).
To determine whether INSL3 might act on intracellular
calcium concentration, we used the fluorescent calcium indicator
FURA-2. No variation in intracellular calcium was observed at
any INSL3 concentration (1 nM, 10 nM, 100 nM) (Figure 4).
Calcium stability was furthermore confirmed by the absence of
PLCb3 phosphorylation [15] (Figure 2).
INSL3 modulates gene expression on human osteoblasts
and stimulates mineralization
Quantitative RT-PCR analysis showed that INSL3 increased
the mRNA level of COL1A1 (collagen type I, alpha 1), COL6A1
(collagen type VI, alpha 1) and osteonectin (Figure 5A, B and C) at all
the concentrations tested. The expression levels of osteopontin and
TGF-b (transforming growth factor, beta 1) were increased only at the
highest INSL3 concentration (100 nM) (Figure 5D and E). These
data showed that INSL3 increases the expression of some
osteoblast genes involved in matrix deposition process.
To elucidate if INSL3 could affect bone remodeling, we
evaluated its role on the transcriptional levels of cytokines that
regulate negatively (OPG - osteoprotegerin) or positively (M-CSF –
Macrophage colony stimulating factor) osteoclastogenesis. INSL3 did not
modify OPG expression (Figure 5G), whereas the effect on M-CSF
mRNA was clearly dose-dependent (Figure 5F). These results
showed that INSL3 positively modulates the osteoclastogenesis
process.
Finally, we analyzed the possible effects of INSL3 on gene
expression of some important osteoblast receptors. AR (androgen
receptor) and VDR [vitamin D (1,25- dihydroxyvitamin D3) receptor],
expressions were not influenced by INSL3 (Figure 5H and I)
whereas PTHR (parathyroid hormone receptor) mRNA level was
increased by INSL3 (Figure 5J). These data showed that INSL3
stimulates only PHTR expression, which is involved in the
regulation of bone mass.
The effect of INSL3 on transcription was confirmed at the
protein level by Western blotting for representative genes (Col6A1,
osteonectin, and M-CSF) (Figure 6).
Alizarin red-S staining showed bone nodules formation in
human osteoblasts treated with INSL3 (Figure 7), confirming the
ability of these cells to mineralize the extracellular matrix.
Discussion
We recently identified the INSL3 receptor RXFP2 on human
osteoblasts surface and demonstrated, by human and animal
studies, the role of this hormone in the proliferation of osteoblasts
and in bone mass regulation [4]. We also showed that INSL3 acts
on human osteoblasts through a RXFP2-mediated increase in
cAMP [4]. In the light of these data we focused our attention on
the molecular events involved in INSL3 signaling in human
osteoblasts.
After demonstrating that INSL3 increases the production of the
most typical osteoblast protein (ALP), here we demonstrate that
the MAPK cascade is the major pathway activated by INSL3 and
that this hormone induces the expression of key osteoblast genes
involved in osteoblast differentiation, matrix deposition and
osteoclastogenesis, and it stimulates mineralization.
GPCRs could activate MEK/ERK and Akt using an intricate
signaling network [16–18] (Fig. 8), and both these signaling
pathways have been implicated in osteoblast differentiation and
proliferation [19,20]. The phosphorylation of ERK is downstream
of Raf and MEK (Fig. 8) and this activation allows ERK to
regulate transcription of target genes in the nucleus [19]. Cyclic-
AMP can regulate MAPK activity via PKA and can either
increase or decrease MAPK signaling depending on the different
cell type [21] (Fig. 8). Phosphorylation of Akt at T308 and S473
leads Akt to move to cytoplasm and nucleus, where it
phosphorylates and activates target proteins involved in different
cellular functions [22] (Fig. 8). Cyclic AMP can also regulate Akt
phosphorylation and activation [21] (Fig. 8). The kinase GSK3b is
downstream of Akt [23] and is constitutively active [17]. GSK-3b
can be inactivated through the phosphorylation at S9 by Akt [17]
or by cAMP [24] (Fig. 8). Moreover, Akt could act, at least in part,
through IKKa to activate canonical NF-kB activity [25] and
GSK3b could suppress NF-kB activity by inhibiting IKK and
stabilizing IkB [26] (Fig 8). The analysis of these different
intracellular signaling pathway moleculaes and their phosphory-
lation status demonstrated that MEK/ERK phosphorylation is the
major pathway involved in INSL3 signaling in human osteoblasts.
Considering also our previous results [4], we can assume that the
MAPK pathway is stimulated by AC/cAMP/PKA.
However, we considered also other pathways that could activate
MAPK signaling, such as cRaf inhibition at S259 [14], PYK2/Src
[27,28], and calcium (Fig. 8). Our data showed that INSL3 does
not affect these signaling molecules, nor it induces calcium as
second messenger via PLCb3 phosphorylation (G protein- or bc-
mediated) or by direct Ca
2+/PKC induction (Fig. 8) [15]. Taken
together, these data demonstrate that MEK/ERK phosphoryla-
tion is the main pathway activated in human osteoblasts by
INSL3. This finding fits well with the known effect of MAPK
signaling in osteoblast proliferation/differentiation [20], and
further supports our previous results [4].
We also examined the Wnt/b-catenin signaling pathway, one of
the most extensively studied pathways with direct relevance to
basic bone biology [29]. The importance of this pathway in bone
formation is undeniable, and it has been demonstrated that the
activation of the b-catenin signaling leads to increase bone mass,
while suppression results in bone loss [29]. b-catenin could be
phosphorylated by GSK3b at S33/S37/T41 or by other kinases as
PKA at S675 and Akt at S552 [30] (Fig. 8). Furthermore, it has
been recently reported a possible link between INSL3 and b-
catenin during gubernaculum development [12]. However, we
excluded this pathway, as our data indicated that INSL3 does not
influence b-catenin phosphorylation in human osteoblasts. The
different results obtained by Kaftanovskaya in gubernacular cells
[12] could be due to a crosstalk of pathways that are not involved
Figure 2. INSL3 effects on protein phosphorylation in human osteoblasts. Western blot analysis for the phosphorylation of proteins
involved in MAPK pathway (cRAF, MEK, ERK), integrin pathway (PYK, Src), b-catenin pathway, calcium pathway (PLCb3), Akt pathway (Akt, GS3b) and
NF-kB pathway (NF-kB, IKKa, IKKb,I kBa). Cells were stimulated with different INSL3 concentrations (1 nM, 10 nM and 100 nM) for a short time period
(5, 10, 15, 30 and 45 minutes). b-actin was used as endogenous control to normalize protein quantity. Control is obtained without stimulation. Figures
are representative of three independent experiments. Ctrl: Control.
doi:10.1371/journal.pone.0029733.g002
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on Akt phosphorylation: A. ELISA at S473, B. densitometric analysis at S473 and C. densitometric analysis at T308. Quantitative analysis on MEK
phosphorylation: D. ELISA and E. densitometric analysis. Quantitative analysis on ERK phosphorylation: F. ELISA and G. densitometric analysis. ELISA
data are shown as the mean 6 standard deviation (SD) of the mean of three different experiments performed in triplicate. Densitometric data are
shown as the mean 6 standard deviation (SD) of the mean of three different experiments. * P,0.05 vs control.
doi:10.1371/journal.pone.0029733.g003
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species (mouse and human).
We next evaluated whether INSL3 stimulates genes involved in
osteoblast proliferation/differentiation, matrix deposition and
osteoclastogenesis. Other than an important effect on ALP
production, we observed a significant effect of INSL3 on the
expression of genes involved in the mineralization process, such as
COL1A1, COL6A1, osteonectin, osteopontin, and TGF-b. The
interaction among osteogenic-related molecules such as COL1A1
is well known as being related to matrix mineralization [31] and
COL6A1 has been suggested to play an important role in matrix-
matrix interaction and in the construction of the extracellular
structure. In some cases of osteoporosis, type VI collagen
significantly decreases in bone suggesting that type VI collagen
Figure 4. Intracellular calcium evaluation with in human osteoblasts stimulated with INSL3. Calcium mobilization (evaluated by FURA-2)
in human osteoblasts after stimulation with A. INSL3 1nM, B. INSL3 10 nM and C. 100 nM. Figures are representative of three independent
experiments.
doi:10.1371/journal.pone.0029733.g004
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e29733Figure 5. Quantitative RT-PCR on osteoblasts stimulated with INSL3. A. COL1A1, B. COL6A1, C. Osteonectin, D. Osteopontin, E. TGF-b, F. M-
CSF, G. OPG, H. AR, I. VDR, J. PTHR. Quantification was normalized to the expression of the housekeeping gene b2-microglobulin on control (no
stimulation). Data are shown as the mean 6 standard deviation (SD) of the mean of three different experiments performed in triplicate. * P,0.05 vs
control. nRQ: normalized Relative Quantity. Ctrl: Control.
doi:10.1371/journal.pone.0029733.g005
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is the most abundant non-collagenous protein of developing bone
and its high levels in forming bone may reflect a high proliferative
potential of the functional osteoblast [33,34]. Osteopontin
comprises about the 2% of the non-collagenous protein in bone
[35] and it has important roles in bone turnover serving as
attachment for osteoclasts activating the resorption cascade [36].
TGF-b is produced by osteoblasts and regulates the proliferation
and differentiation of osteoblasts both in vitro and in vivo [37] by
regulating the production of different genes such as those of the
bone specific extracellular matrix proteins including type I
collagen [38]. INSL3 could therefore have an important role in
matrix deposition as it stimulates the expression of genes coding
for collagenous and non–collagenous proteins. These data well
agree with the finding that INSL3-stimualted osteoblasts are fully
differentiated and are able to mineralize the extracellular matrix.
Furthermore, the increased expression of osteonectin and
osteopontin underlines the effect of this hormone in the cellular
proliferation process.
We previously reported also a reduced osteoclasts population in
Rxfp2
2/2 mice [4], so here we analyzed the effects of INSL3 on
osteoblasts/osteoclasts crosstalk. OPG indirectly inhibits osteoclast
proliferation and activity by blocking the interaction of RANKL
(produced by the osteoblast) with its membrane-bound osteoclast
receptor RANK [39], while M-CSF stimulates osteoclastogenesis
by binding with the c-FMS receptor on osteoclast surface [13]. We
found that INSL3 seems to modulate the osteoclast activity by
stimulating osteoclastogenesis mainly acting on M-CSF expression
rather than OPG. Although we did not analyze RANKL
expression, which is needed to complete osteoclast differentiation,
these data suggest a possible mechanism of action by which INSL3
indirectly affects maturation/differentiation of osteoclasts, and well
agree with our previous findings on Rxfp2
2/2 mice [4].
Finally, we evaluated whether INSL3 could influence the
expression of genes coding for important osteoblast receptors, such
as the androgen receptor (AR) [40], vitamin D receptor (VDR)
[41], and parathyroid hormone receptor (PTHR). Only the latter
is positively regulated by INSL3 and these data again well agree
with our previous experiments on Rxfp2
2/2 mice [4], as PTH
stimulates osteoclast-mediated bone resorption indirectly via the
activation of the PTHR on osteoblasts [42].
Taken together, the findings of the present study shed light into
the molecular and cellular events regulated by INSL3 in human
osteoblasts and into the bone phenotype of men and mice with
disrupted INSL3 signaling previously described by our group [4].
In fact, young adult men with inactivating mutations of the INSL3
receptor have reduced bone mass and higher risk of osteopenia
and osteoporosis despite normal testosterone and INSL3 plasma
concentrations [4]. Rxfp2-deficient mice have decreased bone
volume and alterations of the trabecular bone as a consequence of
a functional impairment of the osteoblasts leading to reduced
mineralizing surface, bone formation rate and osteoclast surface
[4].
The identification of osteoblasts as INSL3 responsive cells and
the association between mutations in the INSL3 receptor gene and
reduced bone density open new perspectives in male osteoporosis.
Our results demonstrate for the first time that the INSL3/RXFP2
system exerts its action on human osteoblasts not only via cAMP
but also activating MAPK pathway. Furthermore, the present
study confirmed that this hormonal signaling plays a dual role in
bone metabolism, inducing both osteoblasts maturation and
osteoclasts differentiation.
Materials and Methods
Cell culture
The primary explant technique from femoral heads discarded
during three arthroplasty (performed by GT) was used to obtain
human osteoblast cultures as previously reported by Velasco et al.
[43]. Their use for in vitro scientific research does not require
Figure 6. Western blotting for Col6A1, osteonectin, and M-CSF
of human osteoblasts stimulated by INSL3. A dose-dependent
increase in protein level is evident, confirming quantitative RT-PCR
results.
doi:10.1371/journal.pone.0029733.g006
Figure 7. Mineralizing ability of human osteoblasts stimulated with INSL3. Mineralized nodule formation was detected by Alizarin red-S
staining and the effect of INSL3 (100 nM) was compared to that of 1,25-vitamin D (100 nM) used as positive control.
doi:10.1371/journal.pone.0029733.g007
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fragments were seeded into T-25 plastic flasks containing DMEM-
F/12 (Euroclone) supplemented with 10% FBS (Euroclone),
50 mg/ml ascorbic acid (Sigma-Aldrich), 10
28 M dexamethasone
(Sigma-Aldrich), and 10 mM b-glycerolphosphate (Sigma-Al-
drich). This allowed osteoblastic precursor cells to migrate from
the fragments, differentiate and proliferate. After confluence, cells
were trypsinized and cultured in the same medium. Third passage
cells were used for the evaluation of the osteoblastic phenotype
with alkaline phosphatase (ALP) staining and for experiments.
Cytochemical ALP staining was performed directly on cell culture
plates using a commercial kit (Sigma-Aldrich) to confirm their
osteoblast phenotype. Cells were observed with a light microscope
and the presence of ALP was indicated by red precipitates. Cells
with almost the 80% of ALP positivity were stimulated with
human INSL3 (Phoenix Pharmaceuticals, Burlingame, CA, USA)
(1 nM, 10 nM and 100 nM) overnight for TUNEL assay, ALP
activity, Western blot, and quantitative real-time PCR, or for a
shorter period (from 5 to 45 minutes) for Western blot and ELISA
analysis. For the Alizarin Red Staining (ARS) cells were incubated
for 15 days with INSL3 (1nM, 10nM, 100nM) or Vitamin D
(100nM) changing the medium every 3–4 days. The employed
INSL3 concentrations bracketed the dissociation constant of
INSL3 for its receptor RXFP2 [44].
Analysis of apoptosis: TUNEL Assay
Cells were fixed for 25 min in 4% paraformaldehyde at room
temperature. Apoptosis (DNA integrity) was evaluated at the single-
cell level using the DeadEnd
TM Fluorometric TUNEL System
(Promega, Milan, Italy) according to the manufacturer’s instruc-
tions. Positive controlwasrepresentedbypre-treatment withDNase
following manufacturer’s instructions. Nuclei were counterstained
using DAPI (Boehringer).Fluorescently labeled fragmentswereseen
under a fluorescent microscope (Leica TCP SP5). All images were
acquired using an oil-immersion 63X objective.
Bone specific alkaline phosphatase (ALP) determination
Cell lysates were obtained incubating cells with a detergent-
containing buffer (0.5% Triton X-100 (Sigma-Aldrich) in 0.1 M
Tris-HCl (Carlo Erba) pH 7.8 for 15 min at 37uC.
To determine intracellular ALP concentration we used Ostase
BAP Immunoenzymetric Assay (Pantec) following manufacture
instructions. Data areshown as themean 6 standard deviation (SD)
of the mean of three different experiments performed in triplicate.
Figure 8. Signaling pathways of INSL3 investigated in human osteoblasts. Continuous lines identify the major pathway stimulated by INSL3
and culminating in MEK/ERK phosphorylation via AC/cAMP/PKA. Dotted lines show excluded pathways in INSL3 signaling from our findings. See text
for details. P: phosphorylation, U: Ubiquitination.
doi:10.1371/journal.pone.0029733.g008
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After treatment with the hormone, cell lysates were obtained by
a physical procedure (freezing in liquid nitrogen and defrosting in
water at 37uC) into lysis buffer containing protease inhibitor.
Lysates were denatured with SDS and 2-b-mercaptoethanol,
boiled and then fractionated using SDS-PAGE gel (Bio-Rad).
After blotting onto Hybond ECL Nitrocellulose Membrane
(Perkin Elmer) and blocking with a 5% milk solution (Bio-Rad),
blots were incubated at 4uC with the primary antibody overnight.
The following rabbit primary antibodies from Cell Signaling
Technology, were used: anti-Src (1:500; 2123), antiphospho-Src
(1:500; 2105), anti-Akt (1:500; 4691), antiphospho-Akt Ser473 XP
(1:500; 4060), antiphospho-Akt Thr308 (1:250; 2965), anti-
ERK1/2 (1:500; 4695), antiphospho-ERK1/2 Thr202/Tyr204
(1:500; 4370), anti-MEK1/2, (1:250; 9122), antiphospho-MEK 1/
2 Ser217/221 (1:250; 9154), anti-GSK3b (1:500; 9315), antipho-
spho-GSK3b (1:500; 9323), antiphospho-cRAF S259 (1:500;
9421), anti-NF-kB (1:500; 4764), antiphospho-NFkB (1:500;
3033), anti-IKKa (1:500; 2682), antiphospho-IkBa (1:500; 2859),
anti-IKKb (1:500; 2678), antiphospho-IKKa/b (1:500; 2697),
anti-PYK (1:500; 3292), antiphospho-PYK (1:100; 3291), anti-b-
catenin (1:500; 9582), antiphospho-b-catenin S552 (1:500; 9566),
antiphospho-b-catenin S675 (1:500; 9567), antiphospho-b-catenin
S33/37/T41 (1:200; 9561). The mouse antibody anti-IkBa (1:500;
4814) from Cell Signaling Technology was also used. The
following rabbit primary antibodies from Santa Cruz Biotechnol-
ogy, were used: anti-PLCb3 (1:100; sc-13958), antiphospho-
PLCb3 (1:50; sc-34392), anti-MCSF (1:100; sc-13103), anti-
osteonectin (1:100, sc-25574), anti-Col6A1 (1:100, sc-20649).
Mouse antibody vs b-actin (1:500; sc-47778 Santa Cruz
Biotechnology) served as an internal control. Antibody binding
to the membrane was detected using a secondary antibody (goat
anti-rabbit IgG 1:5000; Perkin Elmer or goat anti-mouse IgG
1:5000 Calbiochem) conjugated to horseradish peroxidase and
visualized using enzyme-linked chemiluminescence (ECL, Perkin
Elmer) with the Chemidoc XRS System (Bio-Rad). Densitometric
analysis was performed with the Quantity One 4.6.9 software (Bio-
Rad). Data are shown as the mean 6 standard deviation (SD) of
the mean of three different experiments performed in triplicate.
ELISA
Protein extraction for the ELISA assay was performed with the
suggested Cell Lysis Buffer (Cell Signaling Technology). The
quantitative evaluation of phosphorylations were performed with
commercial ELISA form Cell Signal Technology (Akt1 - BK7170,
pAkt1 S473 - BK7160, MEK1 - BK7165, pMEK1 - BK7175,
ERK - BK7177, and pERK - BK7050) following manufacturer’s
instructions. Data are shown as the mean 6 standard deviation
(SD) of the mean of three different experiments performed in
triplicate.
Intracellular calcium concentration measurement
For intracellular calcium measurement, osteoblasts were grown
on round glass coverslips and then loaded with 5 mM FURA-2
(Invitrogen) for 30 minutes at 37uC in saline medium added with
2 ml Pluronic Acid (Invitrogen) and 250 mM Sulfinpyrazone
(Sigma-Aldrich). Fluorescence was monitored with an Olympus
IX 81 inverted microscope by recording and emission signal at
510 nm at 3 seconds intervals excitating at 340 nm and 380 nm.
Cellular vitality was evaluated adding 200 nM Ionomycin
(Invitrogen). Experiments were performed three times in triplicate.
RNA isolation and cDNA synthesis
Total RNA was isolated with RNA-Bee reagent. The amount of
RNA isolated was determined by spectrometry at 260 nm. Total
RNA was used for first-strand cDNA synthesis using the
Superscript III RT kit (Invitrogen) according to the manufacturer’s
instructions. cDNAs were tested by PCR using specific oligonu-
cleotide primers for the housekeeping gene b-Actin (b-Actin forward
59-CACTCTTCCAGCCTTCCTTCC-39 b-Actin reverse 59-
CGGACTCGTCATACTCCTGCTT-39).
Quantitative RT-PCR
Quantitative expression of typical osteoblast genes was evalu-
ated with TaqMan Gene Expression Assays (Applied Biosystems):
Alkaline phosphatase (ALP – Hs00758192_m1), Vitamin D Receptor
(VDR - Hs01045840_m1), Collagen type I (COL1A1 -
Hs00164004_m1), Collagen type VI (COL6A1 - Hs00242448_m1),
Osteoprotegerin (OPG - Hs00171068_m1), Osteonectin (ON -
Hs00234160_m1), Osteopontin (OP - Hs00167093_m1), TGF-b
(Hs00852894_g1), Macrophage Colony Stimulatin Factor (M-CSF -
Hs00174164_m1), Androgen Receptor (AR - Hs00171172_m1) and
Parathyroid Hormone Receptor (PTHR - Hs00174895_m1). Thermal
cycling included initial steps at 50uC for 2 min and 95uC for
10 min, followed by 40 cycles at 95uC for 15 sec and 60uC for
1 min. The fluorescence of the double-stranded products was
monitored in real time. The cDNA was amplified and quantified
using a Sequence Detection System SDS 7900HT (Applied
Biosystems). Data were normalized to an internal housekeeping
gene, using the TaqMan Human b2-microglobulin assay
(Hs00187842_m1), and then on control osteoblasts without INSL3
stimulation. Experiments were performed three times in triplicate.
Data elaboration was performed as relative quantification analysis
using the DDCt method. Data are shown as the mean 6 standard
deviation (SD) of the mean of three different experiments
performed in triplicate.
Alizarin Red-S Staining
Osteoblasts cultured in 6-well plates were washed with PBS and
fixed in 4% (v/v) formaldehyde (Sigma–Aldrich) at room
temperature for 20 min. Cells were then washed twice with excess
deionized water prior to addition of 2% alizarin red-S (Sigma–
Aldrich) (pH 4.1) per well. Plates were incubated at room
temperature for 30 min with gentle shaking. After aspiration of
the unincorporated dye, wells were washed four times with
deionized water while shaking for 5 min. Brown/red staining was
visualized using an inverted microscope (Nikon), and the
representative pictures were photographed. Experiments were
performed in triplicate.
Statistical analysis
Differences in data obtained in real-time gene expression
experiments, proliferation assay, densitometric analysis, ELISA
assay and ALP activity test between controls and osteoblasts
stimulated with INSL3 at different concentration were determined
by paired two-tailed Student’s t-test after acceptance of normal
distribution of the data with the Kolmogorov–Smirnov test.
P,0.05 was considered as statistically significant.
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